|
1
|
Damron TA, Ward WG and Stewart A:
Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National cancer
data base report. Clin Orthop Relat Res. 459:40–47. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Anderson ME: Update on survival in
osteosarcoma. Orthop Clin North Am. 47:283–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Geller DS and Gorlick R: Osteosarcoma: A
review of diagnosis, management, and treatment strategies. Clin Adv
Hematol Oncol. 8:705–718. 2010.PubMed/NCBI
|
|
4
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma (M)//. Jaffe N, Bruland OS and Bielack S: Pediatric
and adolescent osteosarcoma Boston, MA: Springer US; pp. 3–13.
2010
|
|
5
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment and a collaborative
pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bielack SS, Smeland S, Whelan JS, Marina
N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, et
al: Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance
pegylated interferon Alfa-2b versus MAP alone in patients with
resectable high-grade osteosarcoma and good histologic response to
preoperative MAP: First results of the EURAMOS-1 good response
randomized controlled trial. J Clin Oncol. 33:2279–2287. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chang J, Wang Z, Tang E, Fan Z, McCauley
L, Franceschi R, Guan K, Krebsbach HP and Wang C: Inhibition of
osteoblastic bone formation by nuclear factor-kappaB. Nat Med.
15:682–689. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Avnet S, Di Pompo G, Chano T, Errani C,
Ibrahim-Hashim A, Gillie RJ, Donati DM and Baldini N:
Cancer-associated mesenchymal stroma fosters the stemness of
osteosarcoma cells in response to intratumoral acidosis via NF-κB
activation. Int J Cancer. 140:1331–1345. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mongre RK, Sodhi SS, Ghosh M, Kim JH, Kim
N, Sharma N and Jeong DK: A new paradigm to mitigate osteosarcoma
by regulation of MicroRNAs and suppression of the NF-κB signaling
cascade. Dev Reprod. 18:197–212. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tang QL, Xie XB, Wang J, Chen Q, Han AJ,
Zou CY, Yin JQ, Liu DW, Liang Y, Zhao ZQ, et al: Glycogen synthase
kinase-3β, NF-κB signaling, and tumorigenesis of human
osteosarcoma. J Natl Cancer Inst. 104:749–763. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Testa JR and Tsichlis PN: AKT signaling in
normal and malignant cells. Oncogene. 24:7391–7393. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu T, Zhang L, Joo D and Sun SC: NF-κB
signaling in inflammation. Signal Transduct Target Ther.
2:170232017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Germano G, Allavena P and Mantovani A:
Cytokines as a key component of cancer-related inflammation.
Cytokine. 43:374–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peng N, Gao S, Guo X, Wang G, Cheng C, Li
M and Liu K: Silencing of VEGF inhibits human osteosarcoma
angiogenesis and promotes cell apoptosis via VEGF/PI3K/AKT
signaling pathway. Am J Transl Res. 8:10052016.PubMed/NCBI
|
|
15
|
Mirabello L, Troisi RJ and Savage SA:
International osteosarcoma incidence patterns in children and
adolescents, middle ages and elderly persons. Int J Cancer.
125:229–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Behjati S, Tarpey PS, Haase K, Ye H, Young
MD, Alexandrov LB, Farndon SJ, Collord G, Wedge DC, Martincorena I,
et al: Recurrent mutation of IGF signalling genes and distinct
patterns of genomic rearrangement in osteosarcoma. Nat Commun.
8:159362017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang B and Zhang Y, Li R, Li J, Lu X and
Zhang Y: The efficacy and safety comparison of first-line
chemotherapeutic agents (high-dose methotrexate, doxorubicin,
cisplatin, and ifosfamide) for osteosarcoma: A network
meta-analysis. J Orthop Surg Res. 15:512020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Block G, Patterson B and Subar A: Fruit,
vegetables, and cancer prevention: A review of the epidemiological
evidence. Nutr Cancer. 18:1–29. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang J, Li B, Hong S, Liu C, Min J, Hu M,
Li Y, Liu Y and Hong L: Punicalagin suppresses the proliferation
and invasion of cervical cancer cells through inhibition of the
β-catenin pathway. Mol Med Rep. 16:1439–1444. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tang JM, Min J, Li BS, Hong SS, Liu C, Hu
M, Li Y, Yang J and Hong L: Therapeutic effects of punicalagin
against ovarian carcinoma cells in association with β-Catenin
signaling inhibition. Int J Gynecol Cancer. 26:1557–1563. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Omar U, Aloqbi A, Yousr M and Howell NK:
Effect of punicalagin on human colon cancer caco-cells. Malaysian J
Nutri. 22:125–136. 2016.
|
|
22
|
Li Y, Yang F, Zheng W, Hu M, Wang J, Ma S,
Deng Y, Luo Y, Ye T and Yin W: Punica granatum (pomegranate) leaves
extract induces apoptosis through mitochondrial intrinsic pathway
and inhibits migration and invasion in non-small cell lung cancer
in vitro. Biomed Pharmacother. 80:227–235. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Aloqbi A, Omar U, Yousr M, Grace M, Lila
MA and Howell N: Antioxidant activity of pomegranate juice and
punicalagin. Nat Sci. 8:235–246. 2016.
|
|
24
|
Mertens-Talcott SU, Jilma-Stohlawetz P,
Rios J, Hingorani L and Derendorf H: Absorption, metabolism, and
antioxidant effects of pomegranate (Punica granatum L.) polyphenols
after ingestion of a standardized extract in healthy human
volunteers. J Agric Food Chem. 54:8956–8961. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vora A, Londhe V and Pandita N: Herbosomes
enhance the in vivo antioxidant activity and bioavailability of
punicalagins from standardized pomegranate extract. J Funct Foods.
12:540–548. 2015. View Article : Google Scholar
|
|
26
|
Seeram NP, Lee R and Heber D:
Bioavailability of ellagic acid in human plasma after consumption
of ellagitannins from pomegranate (Punica granatum L.) juice. Clin
Chim Acta. 348:63–68. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cerdá B, Espín JC, Parra S, Martínez P and
Tomás-Barberán FA: The potent in vitro antioxidant ellagitannins
from pomegranate juice are metabolised into bioavailable but poor
antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the
colonic microflora of healthy humans. Eur J Nutr. 43:205–220. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cerdá B, Llorach R, Cerón JJ, Espín JC and
Tomás-Barberán FA: Evaluation of the bioavailability and metabolism
in the rat of punicalagin, an antioxidant polyphenol from
pomegranate juice. Eur J Nutr. 42:18–28. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chu G, Zhang W, Chen M, Yang H and Yuan Z:
Punicalagin inhibits RANKL-induced osteoclastogenesis by
suppressing NF-κB and MAPK signaling pathways. Int J Clin Exp Med.
11:6571–6582. 2018.
|
|
30
|
Tang J, Liu C, Min J, Hu M, Li Y and Hong
L: Potential therapeutic role of punicalagin against
mechanical-trauma-induced stress urinary incontinence via
upregulation of Nrf2 and TGF-β1 signaling. Int Urogynecol J.
28:947–955. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Iwatake M, Okamoto K, Tanaka T and Tsukuba
T: Punicalagin attenuates osteoclast differentiation by impairing
NFATc1 expression and blocking Akt-and JNK-dependent pathways. Mol
Cell Biochem. 407:161–172. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Adams LS, Seeram NP, Aggarwal BB, Takada
Y, Sand D and Heber D: Pomegranate juice, total pomegranate
ellagitannins, and punicalagin suppress inflammatory cell signaling
in colon cancer cells. J Agric Food Chem. 54:980–985. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim YE, Hwang CJ, Lee HP, Kim CS, Son DJ,
Ham YW, Hellström M, Han SB, Kim HS, Park EK and Hong JT:
Inhibitory effect of punicalagin on lipopolysaccharide-induced
neuroinflammation, oxidative stress and memory impairment via
inhibition of nuclear factor-kappaB. Neuropharmacology. 117:21–32.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Naugler WE and Karin M: NF-kappaB and
cancer-identifying targets and mechanisms. Curr Opin Genet Dev.
18:19–26. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Toi M, Bando H, Ramachandran C, Melnick
SJ, Imai A, Fife RS, Carr RE, Oikawa T and Lansky EP: Preliminary
studies on the anti-angiogenic potential of pomegranate fractions
in vitro and in vivo. Angiogenesis. 6:121–128. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bakkar N and Guttridge DC: NF-kappaB
signaling: A tale of two pathways in skeletal myogenesis. Physiol
Rev. 90:495–511. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bakkar N, Wang J, Ladner KJ, Wang H,
Dahlman JM, Carathers M, Acharyya S, Rudnicki MA, Hollenbach AD and
Guttridge DC: IKK/NF-kappaB regulates skeletal myogenesis via a
signaling switch to inhibit differentiation and promote
mitochondrial biogenesis. J Cell Biol. 180:787–802. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Londhe P, Yu PY, Ijiri Y, Ladner KJ,
Fenger JM, London C, Houghton PJ and Guttridge DC: Classical NF-κB
metabolically reprograms sarcoma cells through regulation of
hexokinase 2. Front Oncol. 8:1042018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gong T, Su X, Xia Q, Wang J and Kan S:
Expression of NF-κB and PTEN in osteosarcoma and its clinical
significance. Oncol Lett. 14:6744–6748. 2017.PubMed/NCBI
|
|
40
|
Liao CL, Lin JH, Lien JC, Hsu SC, Chueh
FS, Yu CC, Wu PP, Huang YP, Lin JG and Chung JG: The crude extract
of Corni Fructus inhibits the migration and invasion of U-2 OS
human osteosarcoma cells through the inhibition of matrix
metalloproteinase-2/-9 by MAPK signaling. Environ Toxicol.
30:53–63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pan PJ, Tsai JJ and Liu YC: Amentoflavone
inhibits metastatic potential through suppression of ERK/NF-κB
activation in osteosarcoma U2OS cells. Anticancer Res.
37:4911–4918. 2017.PubMed/NCBI
|
|
42
|
Hoesel B and Schmid JA: The complexity of
NF-kappaB signaling in inflammation and cancer. Mol Cancer.
12:862013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lv F, Song LJ, Wang XH, Qiu F and Li XF:
The role of Act1, a NF-κB-activating protein, in IL-6 and IL-8
levels induced by IL-17 stimulation in SW982 cells. Pharm Biol.
51:1444–1450. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Karin M: NF-κB as a critical link between
inflammation and cancer. Cold Spring Harb Perspect Biol.
1:a0001412009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sparmann A and Bar-Sagi D: Ras-induced
interleukin-8 expression plays a critical role in tumor growth and
angiogenesis. Cancer Cell. 6:447–458. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Syed DN, Chamcheu JC, Adhami VM and
Mukhtar H: Pomegranate extracts and cancer prevention: Molecular
and cellular activities. Anticancer Agents Med Chem. 13:1149–1161.
2013. View Article : Google Scholar : PubMed/NCBI
|
